Kairos Pharma (KAPA) VP granted 152,672 RSUs disclosed

Kairos Pharma, Ltd. (KAPA) reported an equity award to its VP of Research and Development on a Form 4.

Accepted by SEC EDGAR 11/26/2025 - 06:50 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Kairos Pharma, Ltd. (KAPA) reported an equity award to its VP of Research and Development on a Form 4. On 10/08/2025, the officer acquired 152,672 restricted stock units (RSUs) of common stock at a price of $0.00 under the company’s 2023 Equity Incentive Plan. These RSUs are scheduled to vest in full on the first anniversary of the grant date.

Following this grant, the officer beneficially owns 299,529 equity interests, consisting of 142,191 shares of common stock and 157,338 RSUs that remain subject to vesting. The filing indicates the holdings are owned directly.

Insider Trade Summary

Grant/Award: 152,672 shares

Grant/Award 1 txn

Insider Murali Ramachandran

Role VP of Research and Development

Type	Security	Shares	Price	Value
Grant/Award	COMMON STOCK	152,672	$0.00	$0.00

Holdings After Transaction: COMMON STOCK — 299,529 shares (Direct)

Footnotes (2)

1. F1. Represents 152,672 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 152,672 RSUs are scheduled to vest in full on the first anniversary of the grant date.
2. F2. Consists of (1) 142,191 shares of common stock and (2) 157,338 RSUs which remain subject to vesting.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Kairos Pharma (KAPA) disclose in this Form 4 filing?

Kairos Pharma disclosed that its VP of Research and Development received 152,672 RSUs of common stock on 10/08/2025 under the 2023 Equity Incentive Plan.

Who is the reporting person in the Kairos Pharma (KAPA) Form 4?

The reporting person is Ramachandran Murali, who serves as Kairos Pharma’s VP of Research and Development and directly owns the reported securities.

How many Kairos Pharma RSUs were granted to the VP on 10/08/2025?

The VP was granted 152,672 restricted stock units (RSUs) of Kairos Pharma common stock, scheduled to vest in full on the first anniversary of the grant date.

What is the total Kairos Pharma equity beneficially owned after this Form 4 transaction?

After the transaction, the officer beneficially owns 299,529 equity interests, including 142,191 shares of common stock and 157,338 RSUs that remain subject to vesting.

At what price were the Kairos Pharma RSUs granted in this Form 4?

The 152,672 RSUs of Kairos Pharma common stock were reported with a transaction price of $0.00, which is typical for RSU grants.

When do the newly granted Kairos Pharma RSUs vest?

The 152,672 RSUs granted to the VP are scheduled to vest in full on the first anniversary of the grant date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Murali Ramachandran

(Last) (First) (Middle)

C/O KAIROS PHARMA, LTD.

2355 WESTWOOD BLVD, #139

(Street)

LOS ANGELES CA 90064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kairos Pharma, LTD. [ KAPA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP of Research and Development

3. Date of Earliest Transaction (Month/Day/Year)
10/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
COMMON STOCK	10/08/2025		A		152,672(1)	A	$0.00	299,529(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents 152,672 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 152,672 RSUs are scheduled to vest in full on the first anniversary of the grant date.

2. Consists of (1) 142,191 shares of common stock and (2) 157,338 RSUs which remain subject to vesting.

	/s/ Ramachandran Murali	11/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.